StreetInsider.com News Articles

Form 8-K Rafael Holdings, Inc. For: Jul 08

Wed, 08 Jul 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260708/26748116.html

Form 8-K Rafael Holdings, Inc. For: Jul 08

Wed, 08 Jul 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260708/26748116.html

Form 4 Rafael Holdings, Inc. For: Jun 21 Filed by: Polinsky David

Tue, 23 Jun 2026 15:33:00 -0400

si-local-file:///var/storage/secattach/20260623/26679213.html

Form 4 Rafael Holdings, Inc. For: Jun 21 Filed by: Polinsky David

Tue, 23 Jun 2026 15:33:00 -0400

si-local-file:///var/storage/secattach/20260623/26679213.html

Form 4 Rafael Holdings, Inc. For: Jun 13 Filed by: JONAS HOWARD S

Tue, 16 Jun 2026 15:55:00 -0400

si-local-file:///var/storage/secattach/20260616/26653867.html

Form 4 Rafael Holdings, Inc. For: Jun 13 Filed by: JONAS HOWARD S

Tue, 16 Jun 2026 15:55:00 -0400

si-local-file:///var/storage/secattach/20260616/26653867.html

Form 10-Q Rafael Holdings, Inc. For: Apr 30

Thu, 11 Jun 2026 08:18:00 -0400

si-local-file:///var/storage/secattach/20260611/26632997.html

Form 10-Q Rafael Holdings, Inc. For: Apr 30

Thu, 11 Jun 2026 08:18:00 -0400

si-local-file:///var/storage/secattach/20260611/26632997.html

Form 8-K Rafael Holdings, Inc. For: Jun 11

Thu, 11 Jun 2026 07:55:00 -0400

si-local-file:///var/storage/secattach/20260611/26632693.html

Form 8-K Rafael Holdings, Inc. For: Jun 11

Thu, 11 Jun 2026 07:55:00 -0400

si-local-file:///var/storage/secattach/20260611/26632693.html

Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results

Thu, 11 Jun 2026 07:30:00 -0400

NEWARK, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the third quarter fiscal year 2026 ended April 30, 2026.

“Yesterday, we were pleased to announce that we reached the completion of the last patient last visit of our pivotal Phase 3 TransportNPC™ trial, and we are grateful for the patients and families, advocacy organizations, and physicians who stood at the heart of this global effort. Together, we have advanced the clinical understanding of NPC, as well as the lived experience of this devastating disease, as we

Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results

Thu, 11 Jun 2026 07:30:00 -0400

NEWARK, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the third quarter fiscal year 2026 ended April 30, 2026.

Form 8-K Rafael Holdings, Inc. For: Jun 10

Wed, 10 Jun 2026 07:49:00 -0400

si-local-file:///var/storage/secattach/20260610/26626816.html

Form 8-K Rafael Holdings, Inc. For: Jun 10

Wed, 10 Jun 2026 07:49:00 -0400

si-local-file:///var/storage/secattach/20260610/26626816.html

Rafael Holdings completes phase 3 study for rare disease treatment

Wed, 10 Jun 2026 07:30:09 -0400

Rafael Holdings Inc. (NYSE: RFL) completed the final patient visit for its pivotal Phase 3 TransportNPC study evaluating Trappsol Cyclo for treating Niemann-Pick Disease Type C, according to a company statement.

The study enrolled 94 patients across 27 sites in 13 countries over 96 weeks. An additional 10 patients participated in a single-arm sub-study focusing on newborns to 3-year-olds as part of a Pediatric Investigational Plan.

The company expects to announce topline results from the main study in the second half of 2026. Rafael Holdings plans to submit a New Drug Application to the FDA during the same timeframe following a completed

Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

Wed, 10 Jun 2026 07:30:00 -0400

Topline results are expected to be announced in second half of calendar 2026

The company has had a pre-NDA meeting with the FDA and expects to submit an NDA in second half of calendar 2026

The company has received acknowledgement from the FDA that our US Expanded Access Program (EAP) can proceed

NEWARK, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today announced the last patient has completed the final 96-week study visit in the pivotal Phase 3 TransportNPC™ study evaluating Trappsol^® Cyclo™ for the treatment of

Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

Wed, 10 Jun 2026 07:30:00 -0400

Topline results are expected to be announced in second half of calendar 2026

The company has had a pre-NDA meeting with the FDA and expects to submit an NDA in second half of calendar 2026

The company has received acknowledgement from the FDA that our US Expanded Access Program (EAP) can proceed

Form 8-K Rafael Holdings, Inc. For: Apr 22

Wed, 22 Apr 2026 07:21:00 -0400

si-local-file:///var/storage/secattach/20260422/26347215.html

Form 8-K Rafael Holdings, Inc. For: Apr 22

Wed, 22 Apr 2026 07:21:00 -0400

si-local-file:///var/storage/secattach/20260422/26347215.html

Rafael Holdings licenses MIT patent for Alzheimer's treatment

Wed, 22 Apr 2026 07:03:36 -0400

Rafael Holdings Inc. (NYSE: RFL) announced that its subsidiary Cyclo Therapeutics entered into an exclusive licensing agreement with Massachusetts Institute of Technology for U.S. Patent No. 12285440. The license covers the use of cyclodextrins in Alzheimer's Disease patients who carry an ApoE4 genetic mutation.

The agreement strengthens the company's intellectual property portfolio around Trappsol Cyclo in treating ApoE4-positive Alzheimer's patients. The ApoE4 gene variant is present in 50-70% of Alzheimer's patients and is considered a key risk factor in developing early onset sporadic Alzheimer's Disease.

Trappsol Cyclo has shown potential to improve cholesterol transport between central nervous system cells. Preclinical data indicate

Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease”

Wed, 22 Apr 2026 07:00:00 -0400

License of the MIT patent strengthens Rafael’s intellectual property around cyclodextrins as an Active Pharmaceutical Ingredient (API) in the treatment of ApoE4-positive Alzheimer’s Disease

NEWARK, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today announced that its subsidiary, Cyclo Therapeutics, has entered into an exclusive licensing agreement with Massachusetts Institute of Technology (“MIT”) covering U.S. Patent No.12285440. This license covers the use of cyclodextrins in patients with Alzheimer's Disease (AD) who carry an ApoE4 genetic mutation, strengthening the company’s intellectual property portfolio around Trappsol^® Cyclo™ in this important AD patient population.

The

Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease”

Wed, 22 Apr 2026 07:00:00 -0400

License of the MIT patent strengthens Rafael’s intellectual property around cyclodextrins as an Active Pharmaceutical Ingredient (API) in the treatment of ApoE4-positive Alzheimer’s Disease

The

Form 4 Rafael Holdings, Inc. For: Mar 21 Filed by: Polinsky David

Tue, 24 Mar 2026 12:24:00 -0400

si-local-file:///var/storage/secattach/20260324/26209168.html

Form 4 Rafael Holdings, Inc. For: Mar 21 Filed by: Polinsky David

Tue, 24 Mar 2026 12:24:00 -0400

si-local-file:///var/storage/secattach/20260324/26209168.html

Form 4 Rafael Holdings, Inc. For: Mar 13 Filed by: JONAS HOWARD S

Tue, 17 Mar 2026 12:48:00 -0400

si-local-file:///var/storage/secattach/20260317/26173294.html